Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19,JAMA

当前位置： X-MOL 学术 › JAMA › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19
JAMA ( IF 63.1 ) Pub Date : 2020-08-04 , DOI: 10.1001/jama.2020.10044
Ling Li _{1,

2} , Wei Zhang _{3,

4} , Yu Hu ₅ , Xunliang Tong ₆ , Shangen Zheng ₇ , Juntao Yang ₈ , Yujie Kong _{1,

2} , Lili Ren _{9,

10} , Qing Wei ₁₁ , Heng Mei ₅ , Caiying Hu ₁₂ , Cuihua Tao _{13,

14} , Ru Yang ₁₅ , Jue Wang _{1,

2} , Yongpei Yu ₁₆ , Yong Guo ₁₇ , Xiaoxiong Wu ₁₈ , Zhihua Xu _{12,

19} , Li Zeng _{3,

20} , Nian Xiong _{12,

21} , Lifeng Chen ₂₂ , Juan Wang ₁₁ , Ning Man ₂₃ , Yu Liu ₁ , Haixia Xu _{1,

2} , E Deng ₁ , Xuejun Zhang ₁ , Chenyue Li _{1,

2} , Conghui Wang ₉ , Shisheng Su ₁₇ , Linqi Zhang ₂₄ , Jianwei Wang _{9,

10} , Yanyun Wu ₂₅ , Zhong Liu _{1,

2}

Affiliation

Institute of Blood Transfusion, Chinese Academy of Medical Sciences and Peking Union Medical College, Chengdu, China.
Key Laboratory of Transfusion Adverse Reactions, CAMS, Chengdu, China.
Guanggu District Maternal and Child Health Hospital of Hubei Province, Wuhan, China.
Department of Respiratory and Critical Care Medicine, First Affiliated Hospital, the Second Military Medical University, Shanghai, China.
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Department of Pulmonary and Critical Care Medicine, Beijing Hospital, National Respiratory quality control center, National Center of Gerontology, Beijing, China.
Department of Transfusion, General Hospital of Central Theater Command of PLA, Wuhan, China.
State Key Laboratory of Medical Molecular Biology, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences & Peking Union, Beijing, China.
NHC Key Laboratory of Systems Biology of Pathogens and Christophe Mérieux Laboratory, Institute of Pathogen Biology, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College, Beijing, China.
Key Laboratory of Respiratory Disease Pathogenomics, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Department of Blood Transfusion, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wuhan Red Cross Hospital, Wuhan, China.
Department of Blood Transfusion, Wuhan Asia Heart Hospital, Wuhan, China.
Department of Blood Transfusion, Wuhan Asia General Hospital, Wuhan, China.
Wuhan Blood Center, Wuhan, China.
Peking University Clinical Research Institute, Peking University Health Science Center, Beijing, China.
Department of Biomedical Engineering, School of Medicine, Tsinghua University, Beijing, China.
Department of Emergency, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Mianyang Central Hospital, Mianyang, China.
Department of Organ Transplantation, First Affiliated Hospital, the Second Military Medical University, Shanghai, China.
Department of Neurology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
Wuhan Pulmonary Hospital, Wuhan, China.
Department of Respiratory Medicine, Wuhan Asia General Hospital, Wuhan, China.
Center for Global Health and Infectious Diseases, Comprehensive AIDS Research Center, and Beijing Advanced Innovation Center for Structural Biology, School of Medicine, Tsinghua University, Beijing, China.
Department of Pathology, University of Miami, Miami, Florida.

Importance Convalescent plasma is a potential therapeutic option for patients with coronavirus disease 2019 (COVID-19), but further data from randomized clinical trials are needed. Objective To evaluate the efficacy and adverse effects of convalescent plasma therapy for patients with COVID-19. Design, Setting, and Participants Open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China, from February 14, 2020, to April 1, 2020, with final follow-up April 28, 2020. The trial included 103 participants with laboratory-confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). The trial was terminated early after 103 of a planned 200 patients were enrolled. Intervention Convalescent plasma in addition to standard treatment (n = 52) vs standard treatment alone (control) (n = 51), stratified by disease severity. Main Outcomes and Measures Primary outcome was time to clinical improvement within 28 days, defined as patient discharged alive or reduction of 2 points on a 6-point disease severity scale (ranging from 1 [discharge] to 6 [death]). Secondary outcomes included 28-day mortality, time to discharge, and the rate of viral polymerase chain reaction (PCR) results turned from positive at baseline to negative at up to 72 hours. Results Of 103 patients who were randomized (median age, 70 years; 60 [58.3%] male), 101 (98.1%) completed the trial. Clinical improvement occurred within 28 days in 51.9% (27/52) of the convalescent plasma group vs 43.1% (22/51) in the control group (difference, 8.8% [95% CI, -10.4% to 28.0%]; hazard ratio [HR], 1.40 [95% CI, 0.79-2.49]; P = .26). Among those with severe disease, the primary outcome occurred in 91.3% (21/23) of the convalescent plasma group vs 68.2% (15/22) of the control group (HR, 2.15 [95% CI, 1.07-4.32]; P = .03); among those with life-threatening disease the primary outcome occurred in 20.7% (6/29) of the convalescent plasma group vs 24.1% (7/29) of the control group (HR, 0.88 [95% CI, 0.30-2.63]; P = .83) (P for interaction = .17). There was no significant difference in 28-day mortality (15.7% vs 24.0%; OR, 0.65 [95% CI, 0.29-1.46]; P = .30) or time from randomization to discharge (51.0% vs 36.0% discharged by day 28; HR, 1.61 [95% CI, 0.88-2.93]; P = .12). Convalescent plasma treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2% of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95% CI, 3.91-33.18]; P < .001). Two patients in the convalescent plasma group experienced adverse events within hours after transfusion that improved with supportive care. Conclusion and Relevance Among patients with severe or life-threatening COVID-19, convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days. Interpretation is limited by early termination of the trial, which may have been underpowered to detect a clinically important difference. Trial Registration Chinese Clinical Trial Registry: ChiCTR2000029757.

更新日期：2020-08-04

点击分享查看原文

点击收藏

公开下载

阅读更多本刊最新论文